HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis

Bone

Volumn 54, Issue 1, 2013, Pages 151-156

  Liu, Jie ^a,b   Zhu, Li Ping ^b   Yang, Xu Li ^c   Huang, He Lang ^c   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Jiangxi Provincial Center for Disease Control and Prevention   (China)

^c NANCHANG UNIVERSITY   (China)

Author keywords

Bone mineral density; HMG CoA reductase inhibitors; Meta analysis; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; ASIAN; BONE DENSITY; CAUCASIAN; CLINICAL EVALUATION; DRUG EFFICACY; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; META ANALYSIS; OSTEOPOROSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY; FEMUR NECK; HIP; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUMBAR VERTEBRAE; MIDDLE AGED;

EID: 84874782291     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.044     Document Type: Article

References (44)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994, 344:1383-1389.
2. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The LlPlD Study Group.
3. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
4. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
5. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001, 280:874-877.
6. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210.
7. Wada Y., Nakamura Y., Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 2000, 160:2865.
8. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., Nicholson G.C. Statin use, bone mineral density, and fracture risk: Geelog osteoporosis study. Arch Intern Med 2002, 162:537-540.
9. Hatzigeorgiou C., Jackson J.L. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 2005, 16:990-998.
10. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
11. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
12. Safaei H., Janghorbani M., Aminorroaya A., Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 2007, 44:76-82.
13. Bauer D.C., Mundy G.R., Jamal S.A., Black D.M., Cauley J.A., Ensrud K., et al. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004, 164:146-152.
14. Chung Y.S., Lee M.D., Lee S.K., Kim H.M. Fitzpatrick LA.HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000, 85:1137-1142.
15. Chuengsamarn S., Rattanamongkoulgul S., Suwanwalaikorn S., Wattanasirichaigoon S., Kaufman L. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 2010, 46:1011-1015.
16. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355:2218-2219.
17. Funkhouser H.L., Tilahun A., Adler R.A. Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J Clin Densitom 2002, 5:152-158.
18. Lupattelli G., Scarpon A.M., Donatella G.V., Siepi D., Roscini A.R., Gemelli F., et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 2004, 53:744-748.
19. Montagnani A., Gonnelli S., Cepollaro C., Pacini S., Campagna M.S., Franci M.B., et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003, 23:427-433.
20. Rejnmark L., Buus N.H., Vestergaard P., Heickendorff L., Andreasen F., Larsen M.L., et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004, 19:737-744.
21. Sirola J., Honkanen R., Kroger H., Jurvelin J.S., Maenpaa P., Saarikoski S. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 2002, 13:537-541.
22. Uysal A.R., Delibasi T., Erdogan M.F., Kamel N., Baskal N., Tonyukuk V., et al. Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract 2007, 13:114-116.
23. Jordan K.M., Cooper C. Epidemiology of osteoporosis. Best Pract Res Cl Rh 2002, 16:795-806.
24. Demir B., Haberal A., Geyik P., Baskan B., Ozturkoglu E., Karacay O., et al. Identification of the risk factors for osteoporosis among postmenopausal women. Maturitas 2008, 60:253-256.
25. Tikiz C., Tikiz H., Taneli F., Gümüşer G., Tüzün C. Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clin Rheumatol 2005, 24:447-452.
26. Perez-Castrillon J.L., Vega G., Abad L., Sanz-Cantalapiedra A., Sagredo M.G., Dd Luis, et al. Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. Ann Nutr Metab 2008, 53:117-121.
27. Watanabe S., Fukumoto S., Takeuchi Y., Fujita H., Nakano T., Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001, 110:584-587.
28. Bone H.G., Kiel D.P., Lindsay R.S., Lewiecki E.M., Bolognese M.A., Leary E.T., et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007, 92:4671-4677.
29. Patil S., Holt G., Raby N., McLellan A.R., Smith K., Kane S.O., et al. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 2009, 27:281-285.
30. Solomon D.H., Finkelstein J.S., Wang P.S., Avorn J. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf 2005, 14:219-226.
31. Nakashima A., Nakashima R., Ito T., Masaki T., Yorioka N. HMG-CoA reductase inhibitors prevent bone loss in patients with type 2 diabetes mellitus. Diabet Med 2004, 21:1020-1024.
32. Tanriverdi H.A., Barut A., Sarikaya S. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005, 120:63-68.
33. Shintani M. Statins with hormone replacement therapy in postmenopausal women with low bone mineral density]. Nihon Rinsho 2004, 62(Suppl. 2):S488-S491.
34. De Leo V., Morgante G., la Marca A., Lanzetta D., Cobellis L., Petraglia F. Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol Endocrinol 2003, 17:329-332.
35. LaCroix A.Z., Cauley J.A., Pettinger M., Hsia J., Bauer D.C., McGowan J., et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative observational study. Ann Intern Med 2003, 139:97-104.
36. Cauley J.A., Jackson R., Pettinger M., Lacroix A., Bauer D., Chen Z., et al. Statin use and bone mineral density in older women: the women's health initiative observational study (WHI-OS). J Bone Miner Res 2000, 15:1068. [Suppl.].
37. Schoofs M.W.C.J., Sturkenboom M.C.J.M., van der Klift M., Hofman A., Pols H.A.P., Stricker BHCH HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004, 19:1525-1530.
38. Yilmaz A., Arikan O., Dokmetas S. Effects of statins on bone mineral density. Saudi Med J 2006, 27:1433-1435.
39. Poole K.E.S., Compston J.E. Osteoporosis and its management. BMJ 2006, 333:1251-1256.
40. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 2001, 12:380-384.
41. Reid I.R., Hague W., Emberson J., Baker J., Tonkin A., Hunt D., et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 2001, 357:509-512.
42. Pérez-Castrillón J.L., Abad L., Vega G., Sanz A., SanMiguel A., Mazón A., et al. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur Rev Med Pharmacol 2008, 12:83-88.
43. Gotoh M., Mizuno K., Ono Y., Takahashi M. Fluvastatin increase bone mineral density in postmenopausal women. Fukushima J Med Sci 2011, 57:19-27.
44. Mallinson J.E., Constantin-Teodosiu D., Sidaway J., Westwood F.R., Greenhaff P.L. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009, 587:219-230.